Location History:
- Gyeonggi-do, KR (2019)
- Hwaseong-si, KR (2021)
Company Filing History:
Years Active: 2019-2021
Title: Innovations of Jin-Hwi Park
Introduction
Jin-Hwi Park is a notable inventor based in Hwaseong-si, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer treatment. With a total of 2 patents, his work is recognized for its potential impact on medical science.
Latest Patents
Jin-Hwi Park's latest patents include a quinazoline derivative or its salt and a pharmaceutical composition comprising the same. This invention provides a quinazoline derivative that exhibits selective inhibitory activity against the phosphatidylinositol 3-kinase delta subunit. This characteristic makes it a promising candidate for preventing or treating cancer while minimizing side effects such as lymphopenia-associated inflammatory responses. Another significant patent is for a benzo[d]thiazole derivative or salt thereof, along with a pharmaceutical composition that includes the same. This compound selectively inhibits the protein-protein interaction between KRS and a laminin receptor, effectively inhibiting the migration of cancer cells. Thus, it holds potential for preventing or treating diseases associated with cancer cell metastasis.
Career Highlights
Jin-Hwi Park is currently associated with Yuhan Corporation, a leading pharmaceutical company in South Korea. His work at Yuhan Corporation has allowed him to focus on innovative solutions in drug development, particularly in oncology.
Collaborations
Some of his notable coworkers include Eui-Chul Lee and Ho-Woong Kang, who contribute to the collaborative efforts in research and development within the company.
Conclusion
Jin-Hwi Park's contributions to pharmaceutical innovations, particularly in cancer treatment, highlight his role as a significant inventor in the field. His patents reflect a commitment to advancing medical science and improving patient outcomes.